VGXI
Private Company
Funding information not available
Overview
VGXI operates as a specialized CDMO focused exclusively on plasmid DNA manufacturing, serving the burgeoning cell and gene therapy and nucleic acid vaccine markets. The company leverages over two decades of expertise and purpose-built facilities to offer scalable GMP production, positioning itself as a critical supplier in the biopharmaceutical supply chain. As a private company, it supports a diverse client base of biotech and pharmaceutical partners, from preclinical stages through commercialization. Its success is tied to the overall growth and regulatory success of the advanced therapy sector.
Technology Platform
Proprietary, scalable GMP manufacturing platform for high-quality plasmid DNA, encompassing high-cell-density fermentation and advanced purification processes.
Opportunities
Risk Factors
Competitive Landscape
VGXI competes in the plasmid DNA CDMO space against larger, diversified CDMOs (e.g., Lonza, Thermo Fisher Scientific) and other specialized players (e.g., Aldevron, a Danaher company). Competition is based on technical expertise, production scale, quality, reliability, and price.